Search COVID-19 Rapid Resource Center or explore resources sorted by Category or Content Type.
Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
From Critical Care Explorations. In this study, the authors evaluate ICU mortality at 28 days in patients with severe hypoxemic respiratory failure due to coronavirus disease 2019 infection who received tocilizumab.
Rajendram P, Sacha GL, Mehkri O, et al.
Estimated Time: 33:18
Categories:
Epidemiology Outcomes, Crisis Management,
Content Type:
Articles,